Literature DB >> 17101665

Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.

Clara Brando1, Lisa A Ware, Helen Freyberger, April Kathcart, Arnoldo Barbosa, Sylvie Cayphas, Marie-Ange Demoitie, Pascal Mettens, D Gray Heppner, David E Lanar.   

Abstract

Liver-stage antigen 1 (LSA1) is expressed by Plasmodium falciparum only during the intrahepatic cell stage of the parasite's development. Immunoepidemiological studies in regions where malaria is endemic suggested an association between the level of LSA1-specific humoral and cell-mediated immune responses and susceptibility to clinical malaria. A recombinant LSA1 protein, FMP011, has been manufactured as a preerythrocytic vaccine to induce an immune response that would have the effect of controlling parasitemia and disease in humans. To evaluate the immunogenicity of FMP011, we analyzed the immune response of three inbred strains of mice to antigen immunization using two different adjuvant formulations, AS01B and AS02A. We report here the ability of BALB/c and A/J mice, but not C57BL/6J mice, to mount FMP011-specific humoral (antibody titer) and cellular (gamma interferon [IFN-gamma] production) responses following immunization with FMP011 formulated in AS01B or AS02A. Immunization of BALB/c and A/J mice with FMP011/AS01B induced more antigen-specific IFN-gamma-producing splenocytes than immunization with FMP011/AS02A. A slightly higher titer of antibody was induced using AS02A than AS01B in both strains. C57BL/6J mice did not respond with any detectable FMP011-specific IFN-gamma splenocytes or antibody when immunized with FMP011 in AS01B or AS02A. Intracellular staining of cells isolated from FMP011/AS01B-immunized BALB/c mice indicated that CD4(+) cells, but not CD8(+) cells, were the main IFN-gamma-producing splenocyte. However, inclusion of blocking anti-CD4(+) antibody during the in vitro restimulation ELISpot analysis failed to completely abolish IFN-gamma production, indicating that while CD4(+) T cells were the major source of IFN-gamma, other cell types also were involved.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101665      PMCID: PMC1828476          DOI: 10.1128/IAI.01075-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  46 in total

1.  Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine.

Authors:  J D Kurtis; M R Hollingdale; A J Luty; D E Lanar; U Krzych; P E Duffy
Journal:  Trends Parasitol       Date:  2001-05

2.  A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay.

Authors:  T W Tobery; S Wang; X M Wang; M P Neeper; K U Jansen; W L McClements; M J Caulfield
Journal:  J Immunol Methods       Date:  2001-08-01       Impact factor: 2.303

Review 3.  The role of intrahepatic lymphocytes in mediating protective immunity induced by attenuated Plasmodium berghei sporozoites.

Authors:  U Krzych; R Schwenk; M Guebre-Xabier; P Sun; D Palmer; K White; I Chalom
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

4.  Host responses to Plasmodium yoelii hepatic stages: a paradigm in host-parasite interaction.

Authors:  A O Lau; J B Sacci; A F Azad
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

5.  The complexity of protective immunity against liver-stage malaria.

Authors:  D L Doolan; S L Hoffman
Journal:  J Immunol       Date:  2000-08-01       Impact factor: 5.422

6.  CD4(+) T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein.

Authors:  Y Charoenvit; V F Majam; G Corradin; J B Sacci; R Wang; D L Doolan; T R Jones; E Abot; M E Patarroyo; F Guzman; S L Hoffman
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  HLA-DQB1*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections.

Authors:  J May; B Lell; A J Luty; C G Meyer; P G Kremsner
Journal:  J Infect Dis       Date:  2000-11-10       Impact factor: 5.226

8.  Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.

Authors:  José A Stoute; Joash Gombe; Mark R Withers; Joram Siangla; Denise McKinney; Melanie Onyango; James F Cummings; Jessica Milman; Kathryn Tucker; Lorraine Soisson; V Ann Stewart; Jeffrey A Lyon; Evelina Angov; Amanda Leach; Joe Cohen; Kent E Kester; Christian F Ockenhouse; Carolyn A Holland; Carter L Diggs; Janet Wittes; D Gray Heppner
Journal:  Vaccine       Date:  2005-12-07       Impact factor: 3.641

9.  Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1).

Authors:  K Bucci; W Kastens; M R Hollingdale; A Shankar; M P Alpers; C L King; J W Kazura
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

10.  Cytokine responses to Plasmodium falciparum liver-stage antigen 1 vary in rainy and dry seasons in highland Kenya.

Authors:  C C John; P O Sumba; J H Ouma; B L Nahlen; C L King; J W Kazura
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

View more
  8 in total

1.  Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1.

Authors:  Ariane Rodríguez; Jaap Goudsmit; Arjen Companjen; Ratna Mintardjo; Gert Gillissen; Dennis Tax; Jeroen Sijtsma; Gerrit Jan Weverling; Lennart Holterman; David E Lanar; Menzo J E Havenga; Katarina Radosevic
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

2.  Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates.

Authors:  S Pichyangkul; U Kum-Arb; K Yongvanitchit; A Limsalakpetch; M Gettayacamin; D E Lanar; L A Ware; V A Stewart; D G Heppner; P Mettens; J D Cohen; W R Ballou; M M Fukuda
Journal:  Infect Immun       Date:  2007-10-22       Impact factor: 3.441

Review 3.  Pre-erythrocytic malaria vaccines: identifying the targets.

Authors:  Patrick E Duffy; Tejram Sahu; Adovi Akue; Neta Milman; Charles Anderson
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

4.  A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria.

Authors:  Stephen A Kaba; Clara Brando; Qin Guo; Christian Mittelholzer; Senthilkumar Raman; David Tropel; Ueli Aebi; Peter Burkhard; David E Lanar
Journal:  J Immunol       Date:  2009-11-13       Impact factor: 5.422

5.  Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates.

Authors:  Rhea J Longley; Ahmed M Salman; Matthew G Cottingham; Katie Ewer; Chris J Janse; Shahid M Khan; Alexandra J Spencer; Adrian V S Hill
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

6.  Identification of adjuvants for clinical trials performed with Plasmodium falciparum AMA1 in rabbits.

Authors:  Sumera Younis; Bart W Faber; Clemens H M Kocken; Edmond J Remarque
Journal:  BMC Immunol       Date:  2019-07-30       Impact factor: 3.615

7.  Spherical nucleic acids as an infectious disease vaccine platform.

Authors:  Michelle H Teplensky; Max E Distler; Caroline D Kusmierz; Michael Evangelopoulos; Haley Gula; Derek Elli; Anastasia Tomatsidou; Vlad Nicolaescu; Ian Gelarden; Anjana Yeldandi; Daniel Batlle; Dominique Missiakas; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-21       Impact factor: 12.779

8.  Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice.

Authors:  Rhea J Longley; Benedict R Halbroth; Katie J Ewer; Adrian V S Hill; Alexandra J Spencer
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.